Sep. 27, 2015, 8:59 AM
- The $8B iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell 4.9% on Friday and 13% for the week - its worst weekly performance since the height of the financial panic seven years ago. Many biotech ETFs eat the same cooking - Gilead (NASDAQ:GILD), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), and Regeneron (NASDAQ:REGN) among the popular names - and FBT, XBI, and BBP fell in amounts similar to IBB.
- The news flow was relatively quiet late in the week, but Hilary Clinton's promise Monday to clamp down on drug prices set things in negative motion for the momo sector.
- Barron's Chris Dieterich reminds that a flood of biotech IPOs in recent years has filled the small cap universe with these highly speculative names, and biotech now makes up 7% of the iShares Russell 2000 Index (NYSEARCA:IWM). Indeed. The IWM fell 3.7% for the week, nearly tripling the decline of the S&P 500.
- ETFs: IWM, TZA, TNA, UWM, VB, VBK, URTY, SCHA, TWM, IWO, RWM, SRTY, VTWO, RCG, JKJ, VTWG, TWOK, FYX, JKK, EWRS, ZSML, FYC, SMLL, RYRSX
Aug. 21, 2015, 3:51 PM
- With the Dow, S&P 500, and Nasdaq all down about 3%, the small-cap Russell 2000 (NYSEARCA:IWM) is lower by just 0.75%.
- The outperformance is noteworthy because it's been small caps leading on the way down - falling nearly 11% since a late-June peak, or roughly 500 basis points worse than the S&P 500.
- ETFs: VB, VBR, EES, VBK, SCHA, RVT, JKL, RCG, JKJ, TILT, FYX, FYT, JKK, IESM, VLU, ZSML, FYC
Sep. 17, 2013, 12:46 PM| Sep. 17, 2013, 12:46 PM | 1 Comment